Investor Presentation Full Year 2021
50
Investor presentation Full year 2021
GLP-1 sourcing is primarily from outside the class but
GLP-1s are still typically used after failure on other products
100%
80%
60%
40%
20%
0%
Metformin
US 'line of usage' across product classes
Share of patients on OADs achieving
HbA1c below 7% in major European countries
SU
DPP-4i
SGLT-2i
GLP-1
1st
2nd
3rd
4th
5th
Note: Data based on data from France, Germany, the UK and the USA only
OAD: Oral anti-diabetic (includes but is not limited to DPP-IV, SGLT-2, metformin and sulfonylurea)
Source: IQVIA Disease Analyser (France, Germany and the UK) and IQVIA LRX (USA), Jun 2018
HbA1c >7%
43%
57%
GLP-1 source of business
(new-to-brand prescription market share)
Insulin and Treatment
GLP-1
naive
5% 5%
Insulin
25%
HbA1c <7%
GLP-1
50%
11%
OAD
Novo NordiskⓇView entire presentation